文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

通过靶向迷走神经治疗心力衰竭。

Treating heart failure by targeting the vagus nerve.

机构信息

Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Piazza Martiri Della Libertà 33, 56127, Pisa, Italy.

Cardiology and Cardiovascular Medicine Division, Fondazione Monasterio, Via G. Moruzzi 1, 56124, Pisa, Italy.

出版信息

Heart Fail Rev. 2024 Nov;29(6):1201-1215. doi: 10.1007/s10741-024-10430-w. Epub 2024 Aug 9.


DOI:10.1007/s10741-024-10430-w
PMID:39117958
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11455679/
Abstract

Increased sympathetic and reduced parasympathetic nerve activity is associated with disease progression and poor outcomes in patients with chronic heart failure. The demonstration that markers of autonomic imbalance and vagal dysfunction, such as reduced heart rate variability and baroreflex sensitivity, hold prognostic value in patients with chronic heart failure despite modern therapies encourages the research for neuromodulation strategies targeting the vagus nerve. However, the approaches tested so far have yielded inconclusive results. This review aims to summarize the current knowledge about the role of the parasympathetic nervous system in chronic heart failure, describing the pathophysiological background, the methods of assessment, and the rationale, limits, and future perspectives of parasympathetic stimulation either by drugs or bioelectronic devices.

摘要

交感神经活性增加和副交感神经活性降低与慢性心力衰竭患者的疾病进展和不良预后相关。尽管采用了现代治疗方法,但自主神经失衡和迷走神经功能障碍的标志物(如心率变异性和压力反射敏感性降低)在慢性心力衰竭患者中具有预后价值,这一发现促使人们研究针对迷走神经的神经调节策略。然而,迄今为止测试的方法并未得出明确的结果。本综述旨在总结目前关于副交感神经系统在慢性心力衰竭中的作用的知识,描述其病理生理学背景、评估方法以及药物或生物电子设备进行副交感神经刺激的原理、局限性和未来展望。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/827f/11455679/a4b92a4e43ed/10741_2024_10430_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/827f/11455679/0f01fd825327/10741_2024_10430_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/827f/11455679/8b6c6a44f4b5/10741_2024_10430_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/827f/11455679/664d005ee554/10741_2024_10430_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/827f/11455679/a4b92a4e43ed/10741_2024_10430_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/827f/11455679/0f01fd825327/10741_2024_10430_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/827f/11455679/8b6c6a44f4b5/10741_2024_10430_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/827f/11455679/664d005ee554/10741_2024_10430_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/827f/11455679/a4b92a4e43ed/10741_2024_10430_Fig4_HTML.jpg

相似文献

[1]
Treating heart failure by targeting the vagus nerve.

Heart Fail Rev. 2024-11

[2]
Skeletal muscle electrical stimulation improves baroreflex sensitivity and heart rate variability in heart failure rats.

Auton Neurosci. 2015-8-28

[3]
Vagal stimulation in heart failure.

J Cardiovasc Transl Res. 2014-2-6

[4]
Autonomic Modulation in Heart Failure: Ready for Prime Time?

Curr Cardiol Rep. 2015-11

[5]
Autonomic regulation therapy suppresses quantitative T-wave alternans and improves baroreflex sensitivity in patients with heart failure enrolled in the ANTHEM-HF study.

Heart Rhythm. 2015-11-18

[6]
Interventional and device-based autonomic modulation in heart failure.

Heart Fail Clin. 2015-4

[7]
Non-invasive vagus nerve stimulation acutely improves spontaneous cardiac baroreflex sensitivity in healthy young men: A randomized placebo-controlled trial.

Brain Stimul. 2017-5-19

[8]
Deep and future insights into neuromodulation therapies for heart failure.

J Cardiol. 2016-11

[9]
A systematic review of the effects of transcutaneous auricular vagus nerve stimulation on baroreflex sensitivity and heart rate variability in healthy subjects.

Clin Auton Res. 2023-4

[10]
Heart failure as an autonomic nervous system dysfunction.

J Cardiol. 2012-2-16

引用本文的文献

[1]
The chronobiology of human heart failure: clinical implications and therapeutic opportunities.

Heart Fail Rev. 2025-1

本文引用的文献

[1]
Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long-term outcomes.

Eur J Heart Fail. 2024-4

[2]
Sympathetic Neural Control at Rest and During the Cold Pressor Test in Patients With Heart Failure With Preserved Ejection Fraction.

Hypertension. 2024-4

[3]
Vagus nerve stimulation for cardiovascular diseases: Is there light at the end of the tunnel?

Trends Cardiovasc Med. 2024-7

[4]
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction.

Card Fail Rev. 2023-6-5

[5]
Potential Cardiologic Protective Effects of Acetylcholinesterase Inhibitors in Patients With Mild to Moderate Dementia.

Am J Cardiol. 2023-8-1

[6]
Endovascular Baroreflex Amplification With the MobiusHD Device in Patients With Heart Failure and Reduced Ejection Fraction: Interim Analysis of the First-in-Human Results.

Struct Heart. 2022-9-16

[7]
A systematic review of the effects of transcutaneous auricular vagus nerve stimulation on baroreflex sensitivity and heart rate variability in healthy subjects.

Clin Auton Res. 2023-4

[8]
Autonomic regulation therapy in chronic heart failure with preserved/mildly reduced ejection fraction: ANTHEM-HFpEF study results.

Int J Cardiol. 2023-6-15

[9]
Chemoreflex and Baroreflex Sensitivity Hold a Strong Prognostic Value in Chronic Heart Failure.

JACC Heart Fail. 2022-9

[10]
Dapagliflozin Improves Cardiac Autonomic Function Measures in Type 2 Diabetic Patients with Cardiac Autonomic Neuropathy.

Anatol J Cardiol. 2022-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索